Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT + Anti-PD-1/PD-L1 in NSCLC
NCT05008861Phase 1Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in non-small cell lung cancer (NSCLC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Incidence of FMT-related Adverse Events at 2 years and Incidence of anti-PD-1/PD-L1-related Adverse Events at 2 years. Status: unknown.
02
Drugs
fecal microbiome transplant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05008861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008861.